Cargando…
Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition
Diffuse large B-cell lymphoma is the most common subtype of lymphoma, representing ∼25 % of non-Hodgkin lymphoid malignancies. EZH2 is highly expressed in Diffuse large B-cell lymphoma and ∼22 % of patients contain EZH2 mutations. EZH2 have been studied as a potential therapeutic target for a decade...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565777/ https://www.ncbi.nlm.nih.gov/pubmed/37829803 http://dx.doi.org/10.1016/j.heliyon.2023.e20650 |